ClinicalTrials.gg
Active, not recruitingNCT06579352Updated Aug 14, 2026

Study of UC-MSC in DMD Patients

A Phase 2 interventional study of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Duchenne Muscular Dystrophy, sponsored by MED Institute Inc.. Active, not recruiting at 2 sites in United States. Open to male participants aged 5 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by MED Institute Inc. (part of Cook Group Incorporated) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
5 Years to 10 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 232 studies in Muscular Dystrophy, Duchenne with a site in United States — 34 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Planned enrollment
76th of 171
35 · median 25
Started
2024
with 14 others
Phase 2
57 of 232
4 open now
Primary completion
2028-10
later than 35 of 59 live
Registered
211th of 232
by date

Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 76th largest by planned enrollment of the 171 interventional ones that give a count, is one of 15 that started in 2024, is one of 57 in phase 2, reaches primary completion later than 35 of the 59 other live ones, and was the 211th registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

34 of the 232 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 12 take healthy volunteers.

This study: 5 Years to 10 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to provide UC-MSC treatment to patients with DMD.

Secondary objectives will be to further evaluate treatment-related adverse events as well as changes in DMD-related functional testing/assessments, blood laboratories, and inflammation related biomarker levels over time.

Read the detailed description

The Phase 2 study will enroll up to 35 ambulatory male participants between the ages of 5 and 10, who will receive four, 3-day intravenous dose cycles of UC-MSC treatment, each administered every three months. Participants will be closely monitored throughout the study period for treatment-related adverse events and changes in DMD-related functional assessments at specific follow-up intervals through 12 months.

03

Conditions studied

  • Duchenne Muscular Dystrophy
04

Who can participate

Ages eligible
5 Years to 10 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male sex by birth with a genetically confirmed diagnosis of Duchenne Muscular Dystrophy (DMD).
  2. Age is greater than or equal to 5 and less than or equal to 10 years.
  3. Has a North Star Ambulatory Assessment (NSAA) score greater than 13 and less than 30.
  4. Demonstrates the ability to perform the "time to rise" test in under 10 seconds.
  5. Is up-to-date on immunizations.
  6. Is on a stable dose of for at least 12 weeks prior to study participation, except for weight-based or toxicity-related adjustments.
  7. Is on a stable dose of supplements for at least 12 weeks prior to study participation.
  8. Has the ability to comply with the requirements of the study and the ability to understand and provide written informed assent and a guardian's consent.
  9. Patient must be either a non-responder to or a poor candidate for treatment with another established therapy.

Exclusion criteria

Exclusion Criteria:

  1. Active cancer or prior diagnosis of cancer within the past year (patients with basal and squamous cell cancer of the skin will not be excluded).
  2. > 45 kg/m².
  3. Any other condition (including concomitant treatment) that, in the judgment of the Investigator or Sponsor, would be a to enrollment, study product administration (e.g., known to dimethyl sulfoxide (DMSO), Human Serum Albumin (HSA), or PlasmaLyte), or follow-up.
  4. Treatment with an exon skipping therapy within 3 months of study start.
  5. Cognitive delay or impairment that can confound motor development in the opinion of the investigator.
  6. Major surgery within 3 months prior to Day 0 or planned surgery or procedures that could affect the conduct of the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    UC-MSC Treatment Group

    Intravenous infusion of UC-MSC

    Biological: Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC)

Interventions

06

What researchers measure

Primary outcomes

  1. Primary Endpoints

    The primary safety endpoint is the rate of treatment-related adverse events over time. The primary efficacy endpoint is the change in DMD-related functional assessments over time.

    Time frame: From enrollment to the end of follow up at 12-months

Secondary outcomes

  1. Secondary Endpoint

    The secondary endpoint is assessment of changes in blood laboratory and inflammation related biomarker levels over time.

    Time frame: From enrollment through follow up at 12-months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Oct 2028, 50 months after the start.

Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 50 months is above that.

Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2024
First posted
Aug 30, 2024
StartActual
Aug 5, 2024
Primary completionEst.
Oct 31, 2028
CompletionEst.
Apr 30, 2029
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06579352
Lead sponsor
MED Institute Inc.
Collaborators
Signature Biologics
Responsible party
Sponsor
First posted
Aug 30, 2024
Start date
Aug 5, 2024
Primary completion
Oct 31, 2028 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Aug 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion